Myasthenia gravis presenting as weakness after magnesium administration.
We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia. The serum magnesium concentration was 3.0 mEq/L, which is usually well tolerated. The magnesium was stopped and she recovered over a few days. While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade. After her strength returned, repetitive stimulation was normal, but single fiber EMG revealed increased jitter and blocking. Her acetylcholine receptor antibody level was markedly elevated. Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease. Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.
Bashuk
R G
RG
Emory University School of Medicine, Department of Neurology, Atlanta, Georgia.
Krendel
D A
DA
D000328:Adult; D003937:Diagnosis, Differential; D004594:Electrophysiology; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D015624:Lambert-Eaton Myasthenic Syndrome / Q000150:complications / Q000175:diagnosis; D008275:Magnesium Deficiency / Q000097:blood; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000009:adverse effects*; D009157:Myasthenia Gravis / Q000150:complications / Q000175:diagnosis*; D010243:Paralysis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011729:Pyridostigmine Bromide / Q000627:therapeutic use
D008278:Magnesium Sulfate; D011729:Pyridostigmine Bromide